What's new? Log in Free sign up

Immutep Limited (IMMP)

Company Profile

Company profile

Ticker

IMMP

Exchange

Website

www.immutep.com

CEO

Mr. Marc Voigt

Incorporated

Location

Fiscal year end

Sector

Health Technology > Biotechnology

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • Alabama Power • Mississippi Power • Teva Pharmaceutical Industries Limited • Abbott Laboratories • Eli Lilly and • Bristol-Myers Squibb • Viatris ...

Former names

Prima BioMed Ltd

SEC CIK

Corporate docs

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

IMMP stock data

1M 3M 6M 1Y

Analyst ratings and price targets

Last 3 months

Latest filings (excl ownership)

View all

Immutep Quarterly Activities Report & Appendix 4C

Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761

Immutep Reports Promising New Data in Head and Neck Cancer

Immutep Announces Initiation of TACTI-004 Phase III Trial

Positive Data from Phase II Trial in Soft Tissue Sarcoma Presented

Current report (foreign)

Immutep Quarterly Activities Report & Appendix 4C

Annual report (foreign)

Immutep Completes Patient Enrolment in Randomised Phase II

Immutep Receives A$3.6 million R&D Tax Incentive from French Government

Latest ownership filings

Altium Capital Management LP

Prima BioMed Ltd

Financial summary

Financial statements Chart IMMP financial data

Quarter (USD)	Jun 24	Jun 23	Jun 22	Jun 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Jun 24	Jun 23	Jun 22	Jun 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Institutional ownership, Q3 2023

IMMP institutional ownership history Ownership history

1.3% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	19	19	–
Opened positions	4	9	-55.6%
Closed positions	4	7	-42.9%
Increased positions	7	1	+600.0%
Reduced positions	3	6	-50.0%

13F shares	Current	Prev Q	Change
Total value	3.63 bn	3.35 bn	+8.2%
Total shares	1.91 mm	1.59 mm	+20.1%
Total puts	161.20 k	142.60 k	+13.0%
Total calls	35.40 k	114.80 k	-69.2%
Total put/call ratio	4.6	1.2	+266.6%

Largest owners	Shares	Value	Change
Millennium Management	786.61 k	$1.49 bn	+359.6%
Oracle Investment Management	516.43 k	$981.22 mm	-42.3%
Meridian Wealth Management	311.20 k	$591.28 mm	+18.3%
Susquehanna International	87.76 k	$166.74 mm	+50.9%
Dimensional Fund Advisors	70.01 k	$133.01 mm	-14.6%
Verition Fund Management	30.00 k	$57.00 mm	+36.4%
BNP Paribas Arbitrage	23.94 k	$45.48 mm	+159.2%
MS Morgan Stanley	22.79 k	$43.31 mm	+1.3%
Geode Capital Management	18.72 k	$35.57 mm	0.0%
Integrated Advisors Network	13.00 k	$24.70 mm	0.0%

Largest transactions	Shares	Bought/sold	Change
Millennium Management	786.61 k	+615.45 k	+359.6%
Oracle Investment Management	516.43 k	-377.96 k	-42.3%
Meridian Wealth Management	311.20 k	+48.15 k	+18.3%
Susquehanna International	87.76 k	+29.61 k	+50.9%
Two Sigma Investments	0.00	-25.65 k	EXIT
BNP Paribas Arbitrage	23.94 k	+14.70 k	+159.2%
HighTower Advisors	12.00 k	+12.00 k	NEW
Dimensional Fund Advisors	70.01 k	-11.92 k	-14.6%
LPL Financial	10.65 k	+10.65 k	NEW
Verition Fund Management	30.00 k	+8.00 k	+36.4%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

News

From Benzinga Pro

Immutep Completes Enrolment Of 40 Patients In Phase II EFTISARC-NEO Trial Evaluating Efti With Radiotherapy And KEYTRUDA For Soft Tissue Sarcoma; Data Updates Expected In 2025; Achieved A Three-Fold Increase In Tumour Hyalinization/Fibrosis; No Grade ≥3 Toxicities Reported

Phase II trial evaluating efti in combination with radiotherapy plus KEYTRUDA® (pembrolizumab) in patients with soft tissue sarcoma reaches enrolment target of 40 patientsData updates from EFTISARC-NEO expected in

Immutep Reported Patient Enrolment Completed for EFTISARC-NEO Phase II Trial

Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces that patient

Immutep Announces That Patient Enrolment Has Been Completed In The Investigator-Initiated INSIGHT-003 Trial

Multi-centre trial evaluating efti in combination with pembrolizumab and chemotherapy in patients with non-small cell lung cancer reaches enrolment target of approximately 50 evaluable patientsData updates from

Immutep And Monash University Announce First Publication In "Science Immunology" Detailing How Human LAG-3 Binds to MHC Class II

Immutep Reports New Data In Head And Neck Cancer At ESMO Immuno-Oncology 2024; Complete Response Rate Increases To 12.9% And 16.1%, According To RECIST 1.1 And iRECIST, Respectively; Treatment Continues To Be Well Tolerated

Press releases

From Benzinga Pro

Immutep Quarterly Activities Report Q2 FY25

Media Release Marking Immutep's transition to a Phase III biotech, the Company's pivotal TACTI-004 trial in first-line non-small cell lung cancer (1L NSCLC) received first regulatory approvalMature data from INSIGHT-003

Immutep Reports Promising New Data in Head and Neck Cancer at ESMO Immuno-Oncology 2024

Data shows strong overall survival, progression-free survival, and durability from novel combination of efti in combination with pembrolizumab in difficult-to-treat head and neck cancer patients with PD-L1 CPS

Immutep's Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung Cancer

Media Release Mature data in patients with a minimum follow-up of 22 months (N=21) shows excellent results, well above historical controls and exceeding expectations: Median Overall Survival is 32.9 months, with median

Positive Data from Phase II Trial in Soft Tissue Sarcoma Presented at CTOS 2024 Annual Meeting

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.